SMARCA4 and non-small cell lung carcinoma: In NSCLC, co-mutations with genetic alterations in KEAP1, SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4), and CDKN2A (cyclin dependent kinase inhibitor 2A) are associated with inferior clinical outcomes to sotorasib therapy (94).